MARKET

FSTX

FSTX

F-star Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.30
+0.01
+0.19%
Closed 16:00 07/28 EDT
OPEN
5.39
PREV CLOSE
5.29
HIGH
5.61
LOW
5.23
VOLUME
83.54K
TURNOVER
--
52 WEEK HIGH
15.50
52 WEEK LOW
3.880
MARKET CAP
102.64M
P/E (TTM)
-0.6028
1D
5D
1M
3M
1Y
5Y
BRIEF-F-Star Therapeutics Provides Interim Update On SB 11285 Study
reuters.com · 2d ago
F-star Therapeutics Says Early Data From SB 11285 'Encourage Further Dose Escalation'
F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of
Benzinga · 2d ago
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
Study is Evaluating Intravenously Administered Novel STING Agonist Alone and In Combination with AtezolizumabCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Compan...
GlobeNewswire · 2d ago
F-star (FSTX), AstraZeneca Team Up for Novel STING Inhibitors
Zacks.com · 07/09 15:02
F-star Therapeutics to Present at Upcoming Investor Conferences
Company Leadership will Speak at Ladenburg Thalmann 2021 Healthcare Conference and the William Blair 2021 Biotech Focus ConferenceCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a ...
GlobeNewswire · 07/09 12:00
Why F-Star Therapeutics Shares Are Trading Higher Today
F-Star Therapeutics (NASDAQ: FSTX) shares are trading higher after the company entered into an exclusive licensing agreement with AstraZeneca (NASDAQ: AZN) for its STING Inhibitors. 
Benzinga · 07/08 17:11
Aerpio Pharmaceuticals, GBS leads healthcare gainers; Virpax Pharmaceuticals, Nephros among major losers
Gainers: Aerpio Pharmaceuticals (ARPO) +54%, GBS (GBS) +25%, 9 Meters Biopharma (NMTR) +19%, Alterity Therapeutics (ATHE) +10%, F-star Therapeutics (FSTX) +9%.Losers: Virpax Pharmaceuticals (VRPX) -13%, Nephros (NEPH) -12%, OncoSec Medical (ONCS) -11%, Aes...
Seekingalpha · 07/08 15:05
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021
 
Benzinga · 07/08 14:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FSTX. Analyze the recent business situations of F-star Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FSTX stock price target is 28.14 with a high estimate of 39.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 64
Institutional Holdings: 5.64M
% Owned: 29.11%
Shares Outstanding: 19.37M
TypeInstitutionsShares
Increased
6
184.87K
New
7
307.74K
Decreased
3
45.33K
Sold Out
2
46.29K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.43%
Pharmaceuticals & Medical Research
+1.83%
Key Executives
Non-Executive Chairman/Independent Director
Nessan Bermingham
President/Chief Executive Officer/Director
Eliot Forster
Chief Financial Officer/Treasurer
Darlene Deptula-Hicks
Chief Scientific Officer
Neil Brewis
Other
Louis Kayitalire
Independent Director
David Arkowitz
Independent Director
Edward Benz
Independent Director
Todd Brady
Independent Director
Pamela Klein
Independent Director
Patrick Johan Hendrik Krol
Independent Director
Geoffrey Race
No Data
About FSTX
F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.

Webull offers kinds of F-Star Therapeutics Inc stock information, including NASDAQ:FSTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FSTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FSTX stock methods without spending real money on the virtual paper trading platform.